CPC A61K 39/39558 (2013.01) [A61K 39/39541 (2013.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/572 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/035 (2013.01); C07K 2319/33 (2013.01); Y02A 50/30 (2018.01)] | 30 Claims |
1. A method of activating T-cells of a patient with cancer comprising administering an anti-PD-L1 antibody and an anti-PVRIG antibody to said patient, wherein said anti-PVRIG antibody comprises:
i) a heavy chain comprising SEQ ID NO: 9, and
ii) a light chain comprising SEQ ID NO: 14.
|